Carlos Grijalva, MD, MPH, FIDSA

Dr. Grijalva is a tenured Professor at Vanderbilt University Medical Center in the Division of Pharmacoepidemiology, with appointments across several centers, including the Vanderbilt Epidemiology Center and the Veterans Affairs Tennessee Valley GRECC. His research focuses on acute respiratory infections, medication and vaccine safety, and comparative effectiveness methodologies. He has extensive experience in observational studies related to influenza and SARS-CoV-2 and has published over 290 peer-reviewed articles, with more than 23.1 thousand citations.

Currently, Dr. Grijalva serves as Co-Principal Investigator for a multicenter study on influenza and SARS-CoV-2 transmission in households and for a cohort study of viral infections among essential workers in Tennessee. Additionally, he leads a NIH K24 grant focused on mentoring related to viral transmission. He has conducted international studies on respiratory viruses in Peru and oversees the Vanderbilt PROgRESS postdoctoral training program and the LHSS K12 training program.

His teaching portfolio includes directing courses in the Vanderbilt Master of Public Health program and mentoring students and faculty who have successfully launched their careers in academia. Dr. Grijalva has received several awards, including the Vanderbilt John S. Sergent Award for Excellence in Teaching and recognition as a Fellow of the Infectious Disease Society of America. In 2022, he was honored with a Special ISPE Award for his public health contributions during the COVID-19 pandemic.